Literature DB >> 12049533

Genotype-phenotype analysis in multiple endocrine neoplasia type 1.

Maria A Kouvaraki1, Jeffrey E Lee, Suzanne E Shapiro, Robert F Gagel, Steven I Sherman, Rena V Sellin, Gilbert J Cote, Douglas B Evans.   

Abstract

HYPOTHESIS: Multiple endocrine neoplasia type 1 (MEN 1) syndrome is an autosomal dominant disorder caused by germline mutations in the MEN1 gene and characterized by multiple endocrine tumors, most notably in the parathyroid glands, pituitary, and pancreas. The syndrome demonstrates variable expressivity and considerable genetic heterogeneity. Patient data were examined for possible associations between genotype and phenotype.
DESIGN: We reviewed recorded medical data from 1975 to 2001 on patients with MEN 1 and compared specific types and locations of MEN1 gene mutations with manifestations of the syndrome. PATIENTS AND
RESULTS: We identified 109 affected patients from 24 MEN 1 kindreds. The phenotypic expression of MEN 1 in affected individuals included hyperparathyroidism in 74%, pancreatic endocrine tumors in 51%, and pituitary tumors in 35%. Twelve of 14 insulinomas occurred in patients with pituitary tumors. Mutation analysis was completed in 14 of 24 kindreds (80 of the 109 patients). Mutations were most common in exons 2 (31%), 9 (15%), and 10 (23%). All 21 patients with frameshift mutations (and known pancreatic endocrine tumor status) had such tumors. Pituitary tumors were associated with frameshift mutations in exon 2.
CONCLUSIONS: The type and location of MEN1 mutations may be associated with the phenotypic expression of specific tumors. Such information may assist in the genetic counseling and surveillance of at-risk patients. A specific genotype-phenotype correlation is unlikely because of the heterogeneity of the mutations in the MEN1 gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049533     DOI: 10.1001/archsurg.137.6.641

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  39 in total

1.  Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

2.  Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias.

Authors:  Francesco Tonelli; Geri Fratini; Gabriella Nesi; Maria Silvia Tommasi; Giacomo Batignani; Alberto Falchetti; Maria Luisa Brandi
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

3.  Intracranial ependymoma associated with multiple endocrine neoplasia type 1.

Authors:  A Al-Salameh; P François; S Giraud; A Calender; A-M Bergemer-Fouquet; L de Calan; P Goudet; P Lecomte
Journal:  J Endocrinol Invest       Date:  2010-02-05       Impact factor: 4.256

4.  Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Maria A Kouvaraki; Suzanne E Shapiro; Gilbert J Cote; Jeffrey E Lee; James C Yao; Steven G Waguespack; Robert F Gagel; Douglas B Evans; Nancy D Perrier
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

5.  Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors.

Authors:  E B Conemans; G M Raicu-Ionita; C R C Pieterman; K M A Dreijerink; O M Dekkers; A R Hermus; W W de Herder; M L Drent; A N A van der Horst-Schrivers; B Havekes; P H Bisschop; G J Offerhaus; I H M Borel Rinkes; G D Valk; H Th M Timmers; M R Vriens
Journal:  J Endocrinol Invest       Date:  2017-11-13       Impact factor: 4.256

6.  Analysis of genotype-phenotype correlations and survival outcomes in patients with primary hyperparathyroidism caused by multiple endocrine neoplasia type 1: the experience at a single institution.

Authors:  Kiyomi Horiuchi; Takahiro Okamoto; Masatoshi Iihara; Toshihiko Tsukada
Journal:  Surg Today       Date:  2012-10-09       Impact factor: 2.549

7.  Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1.

Authors:  Maria D Balsalobre Salmeron; Jose Manuel Rodriguez Gonzalez; Joan Sancho Insenser; Joan Sancho Fornos; Albert Goday; Nuria Maria Torregrosa Perez; Antonio Rios Zambudio; Pascual Parrilla Paricio; Antonio Sitges Serra
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

8.  Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Authors:  P Lecomte; C Binquet; M Le Bras; A Tabarin; C Cardot-Bauters; F Borson-Chazot; C Lombard-Bohas; E Baudin; B Delemer; M Klein; B Vergès; T Aparicio; E Cosson; A Beckers; Ph Caron; O Chabre; Ph Chanson; H Du Boullay; I Guilhem; P Niccoli; V Rohmer; J Guigay; C Vulpoi; J Y Scoazec; P Goudet
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

Review 9.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

10.  Unusual presentation of multiple endocrine neoplasia type 1 in a young woman with a novel mutation of the MEN1 gene.

Authors:  Katalin Balogh; Attila Patócs; Judit Majnik; Fatima Varga; György Illyés; László Hunyady; Károly Rácz
Journal:  J Hum Genet       Date:  2004-06-16       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.